SCHEMBL15565313

SCHEMBL15565313

OCCOCCOc1ccc(CO)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
USP2 O75604 1/20 0.61
LMNA P02545 1/20 0.61
CYP3A4 P08684 1/20 0.61
MAPK1 P28482 1/20 0.61
CASP1 P29466 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
SLCO1B3 Q9NPD5 1/20 0.61
SLCO1B1 Q9Y6L6 1/20 0.61
APP P05067 10/20 0.57
L3MBTL1 Q9Y468 1/20 0.50
HRH3 Q9Y5N1 1/20 0.47
RECQL P46063 1/20 0.47
LTA4H P09960 1/20 0.44
NR1I2 O75469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10600450 0.94 MAPK1 (0.53) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL3085759 0.89 APP (0.67) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL24303208 0.89 APP (0.67) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL5469617 0.88 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL5461109 0.88 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL5459854 0.88 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL5474873 0.88 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL466232 0.87 APP (0.65) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL5902519 0.87 ALDH1A1 (0.60) ALDH1A1MEN1KMT2AUSP2LMNA
SCHEMBL11649743 0.87 HRH3 (0.56) ALDH1A1MEN1KMT2AUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
CN-113754589-B Compositions, methods, and systems for synthesizing and using contrast agents 蓝瑟斯医学影像公司 2024-09-27 CN disclosed
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2024-03-28 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
CN-113754589-A Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-12-07 CN disclosed
CN-107311935-B Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-10-08 CN disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-06-01 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
EP-2882719-A2 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS Lantheus Medical Imaging, Inc. (US) 2015-06-17 EP disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 WO disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 ALDH1A1 3833/4885MEN1 57/4885KMT2A 4131/4885
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 ALDH1A1 3040/4885MEN1 77/4885KMT2A 4341/4885
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 ALDH1A1 3833/4885MEN1 57/4885KMT2A 4131/4885
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 ALDH1A1 3040/4885MEN1 77/4885KMT2A 4341/4885
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 ALDH1A1 3040/4885MEN1 77/4885KMT2A 4341/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 ALDH1A1 3040/4885MEN1 77/4885KMT2A 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.